Stockscreener 앱 받기
1.51
9.04%
-0.15
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
HOKA Trail Shoe Guide: Is Jasper Therapeutics Inc. Equity Warrant stock attractive for long term wealth buildingBest Sellers Snapshot & walk-ready comfort choices - ulpravda.ru
Jasper Therapeutics reports updated data from briquilimab studies - Yahoo Finance
Jasper Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Sahm
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - Sahm
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria - TipRanks
Jasper Therapeutics Reports Positive Data from Briquilimab Studies - TradingView — Track All Markets
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition By Investing.com - Investing.com Nigeria
Jasper Therapeutics stock rises after leadership changes By Investing.com - Investing.com Canada
Jasper Therapeutics stock rises after leadership changes - Investing.com
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition - Investing.com
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of ... - Bluefield Daily Telegraph
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Anticipates Growth with Briquilimab Highlights - timothysykes.com
Why Is Jasper Therapeutics Stock Surging Tuesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Can Jasper Therapeutics’ Progress Propel Its Stock? - timothysykes.com
JSPR Explodes on Briquilimab Asthma Breakthrough - RagingBull
Jasper stock jumps after positive asthma study results - Investing.com India
Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study - Nasdaq
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - Sahm
Jasper Therapeutics Reports Positive Data from ETESIAN Study and BEACON Investigation - TradingView
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in ... - Enidnews.com
Jasper Stock Jumps After Promising New Asthma Study Results - Sahm
Jasper Therapeutics To Host Webinar To Present BEACON And ETESIAN Study Results - Nasdaq
0.90%
자본화:
|
볼륨(24시간):